

MRC-NIHR Trials Methodology Research Partnership: Webinar recording

Trials methodology: a community approach

Presented by Prof Paula Williamson

4 May 2022

On behalf of the TMRP

The slides are also available below.

For any queries, please contact uktmn@nottingham.ac.uk

https://www.youtube.com/watch?v=2tOpaxnJTFk





Trials methodology: a community approach

Professor Paula Williamson University of Liverpool Lead, TMRP

Improving health by improving trials











2021 Cochrane-REWARD prize winners

This year was particularly competitive, with many very strong contenders for the prize committee to consider. Thank you to all who submitted nominations, and congratulations to the winners below:















Enabling research by sharing knowledge



HDRUK Health Data Research UK















A sense of community

"The TMRP has provided me with many opportunities to meet and work with researchers, including other PhD students, outside of my university. Not only has this widened my research experience beyond my PhD but it has also allowed me to meet and work with experts in this field at a time where networking can be particularly challenging in the virtual world. I have benefitted from training courses and other opportunities."

"Academics are part of a community who happen to work at a particular institution. Institutional affiliation is only a part of our identity."





What can a trials methodology network achieve?

- Better, more impactful research
- Less duplication of effort
- Value for money
- Increased knowledge exchange
- Agility ability to pivot to COVID-19 projects

What have we done?

- Priority setting exercises referenced in funding applications
- Small project awards (5-20K), unfunded projects, external grants
- Development and maintenance of online resources
- Open webinar series
- 'How to be a good CI', 'How to be a good TSC Chair', 'How to be a good TM'

COVID-19 related activities 2020-2022

- Adaptive Designs Working Group
- Platform trials: RECOVERY, AGILE, HEAL-COVID

• Statistical Analysis Working Group

- Rapid, open reviews of protocols, preprints and publications on new COVID-19 treatments

• Outcomes Working Group

- COS: acute COVID-19, transmission prevention, Long COVID

• Trial Conduct Working Group

- Contributed to the NIHR INCLUDE Ethnicity Framework



ORBIT: Outcome Reporting Bias in Trials

O 🖽 📄

COC. C

ORRCA and ORRCA II: Online Resource for Recruitment Research in Clinical TriAls

) 🤝 🕄 🔜 🕼 🌾 11:53 💭 🛛 📲 🔎 Type here to search

randomised designs

0

A list of some external resources of use to trialists can be found here.

🚹 Hu... 👷 🎘 🚳 🧤 🛢 🦃 💯 🤝 🐯 📾 🕬 %

HI 🚞

Planning – stratified medicine

💽 Staf	Intranet - I	Jniversity of Live $ imes$	🔯 Mail -	prw@liverpo	ol.ac.uk ×	Biomarker-guided trial de	esigns ×	+				-	٥	×
\leftarrow	\rightarrow C	6	08	www.big	ted.org					☆	\bigtriangledown	$ \pm $	hi/	Ξ
1	BiG	ЭТеD		line tool to h	onalized medici	sonalised medicine Back ine is a growing area of r	esearch v	which aims to tailor the treatment g						^
() () ()	 Treatment A Treatment B Treatment C Treatment C 								validity cludinş ns can lating underta nt pap r on nc	and g Phase be aken a ers, an on-				
	Adaptive Designs													
Following a literature review we have identified eight distinct biomarker-guided adaptive designs, as follows:														
		Jniversity of Live×		prw@liverpo		Biomarker-guided trial de	esigns ×	+		٥	_	_	Lu	~
←	→ C	ഫ	VE	🗟 www.big	ted.org							⊻	hi/	-
						Adaptiv	e De	esigns						
Follov	vin <mark>g</mark> a lite	rature review we	have iden	ntified eight	distinct bioma	rker-guided adaptive de	signs, as	follows:						
Adaptive Signature design				n	Outcome-based adaptive Adaptive threshold sample- randomization design enrichment design				Adaptive patient enrichment design					
Adaptive parallel Simon two- stage design				' ^{o-} N	Multi-arm multi-stage designs Stratified adaptive design				Tandem two stage design					
	Non-Adaptive Designs													
In the review, five distinct non-adaptive trial designs were identified, as follows:														
www.biat		n gle Arm Des ptiveDesigns/Stratifie		Design.html	Enriche	ment Designs		Randomize-All Designs		Biomarker-Strates	gy De	signs	5	~

Planning – adaptive designs

Wilson et al. BMC Medicine (2021) 19:251 https://doi.org/10.1186/s12916-021-02124-z

BMC Medicine

RESEARCH ARTICLE

Open Access

Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project



Nina Wilson¹, Katie Biggs², Sarah Bowden³, Julia Brown⁴, Munyaradzi Dimairo², Laura Flight², Jamie Hall², Anna Hockaday⁴, Thomas Jaki^{5,6}, Rachel Lowe⁷, Caroline Murphy⁸, Philip Pallmann⁷, Mark A. Pilling⁹, Claire Snowdon¹⁰, Matthew R. Sydes¹¹, Sofía S. Villar⁵, Christopher J. Weir¹², Jessica Welburn², Christina Yap¹⁰, Rebecca Maier^{1,13}, Helen Hancock^{1,13} and James M. S. Wason^{1*}

Abstract

Background: Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources are required to conduct a high-quality adaptive clinical trial, compared to a traditional fixed design. The Costing Adaptive Trials (CAT) project investigated which additional resources may be required to support adaptive trials.

Planning – choosing the outcomes to measure

Network Hubs :: Guidance pack × COMET Initiative Resources × +												×
÷	\rightarrow C	\rightarrow C \triangle https://www.comet-initiative.org/Resources \square \bigtriangleup										
	Home	Search the COM	ET Database	Resources	COS Endorsement	COS Uptake	Patients and the Public	Events	About us			^
	COMET	VIII									;	

Ο ΙΠΙΤΙΑΤΙVE

Resources Database Systematic reviews of This section of the website includes useful resources and tools. A trio of guidance for COS development now exists, in addition to the COMET Handbook. COS Click the links below for more information. Newsletter COS-STAP COS-STAD COS-STAR Plain language R Trials PLOS MEDICINE BROWSE PUBLISH ABOUT PLOS MEDICINE BROWSE PUBLISH ABOUT summaries Home About Acticles In Review Submission Guidelines News G DEEN ACCESS D DEDLACTED OUTELNES AND OLIGINAL Research | Open Access | Open Peer Review | Published: 11 February 2019 Patients and the DUERLINE'S AND DURSANCE Core Outcome Set-STAndards for Development: The COS-Core Outcome Set-STAndardised Protocol Items: the Public Core Outcome Set-STAndards for Reporting: The COS-STAR STAD recommendations **COS-STAP** Statement Statement ener J. Kirkham, Kameres Davis, Douglas G. Alman, Jane M. Blandy, Mila Carke, Sean-Tunis, Paula R. Williamoor 🖬 amie J. Kritham, Sarah Gorat, Douglas G. Altman, Jame M. Blazelov, Mile Clarke, Declar Devane, Elizabeth Garao 2017 · https://doi Jamie J. Kirkham, Sarah Gorst, Douglas G. Altman, Jane M. Blazeby, Mike Clarke, Sean Tunis, Paula R. and Milter, Jochen Schmitt, Peter Tugeell, Sean Tures, Paula R. Williamson 🖬 Downloadable slide Williamson S& for the COS-STAP Group ubished. October 10, 2016 + https://doi.org/10.1371/journal.prood.1002140 Trials 20, Article number: 116 (2019) Cite this article set 1511 Accesses | 15 Altmetric | Metrics Links 🜔 11°C 📻 🗞 💿 🧖 💆 🥏 🎲 💷 🕅 🕧 🦟 11.58 23/04/2022 11:58 Ξi Ω 0 P 🗄 Type here to search 0

Conduct – recruitment and retention research



Trial Conduct Working Group - Funding Awards



INITIAL: Involving patients and the public In sTatistIcal Analysis pLans

Determining the most important methodological areas requiring methodological research for routine data in trials: a consensus





Minority ExpeRiences In Trials (MERIT): Understanding why ethnic minority groups are under-represented in trials through a rapid qualitative evidence synthesis, and mapping evidence to find solutions

Beyond "must speak English": In search of a fairer way to operationalise patient screening for language proficiency in trial recruitment



Analysis

BMJ

RESEARCH

Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists

"When I take a look at the data I see what best advances the story, and if you include too much data the reader doesn't get the actual important message, so sometimes you get data that is either not significant or doesn't show anything, and so you, we, just didn't include that"





Citation Analysis for JAMA article

November 2020: viewed 80K times with >22K downloads, 124 citations

Primary reason for citation	2018	2019	2020	Grand		
				Total	Country of first	
Guidance used as a template	6	8	28	42 🗖	author	
Reporting and transparency	7	8	11	26	UK	15
Recommending use of guidance	1		9	10	Denmark	6
Future SAP will follow guidelines	1	4	3	8	Australia	4
Discussion of statistical methods	2	2	2	6	USA	4
Justification for a SAP element	1	3	2	6	Canada	3
Other guideline development	1	1	2	4	Netherlands	2
Other		1	2	3	unknown	2
Application outside RCT		2		2	Saudi Arabia	1
Data sharing methods		1		1	China	1
Cross referencing guidelines			1	1	Chile	1
Grand Total	19	30	60	109*	Italy	1
					Finland	1

Germany

1

15 citations excluded (7 duplicates, 4 awaiting access, 1 citation could not be confirmed, 3 editorial /letters associated with the original publication)

Analysis

"Subgroup analyses in randomised controlled trials frequently categorise continuous subgroup information" (Faye Williamson et al, submitted)



Ensuring clinical trials answer the questions of interest: Implementation of the estimand framework



28th April 2022, 9.30-12.30, Online meeting What are estimands and why should we be using them?

Want to know what an estimand is? What an intercurrent event is? The principles of the estimand framework and why we should be following this?

29th April 2022, 9.30-13.45, Online workshop How to implement the estimand framework





Reporting and sharing findings

- CONSORT-PRO
- CONSORT-Adaptive Design
- CONSORT- and SPIRIT-Surrogate
- SPIRIT-Routine
- Tool to assess outcome reporting bias, <u>http://www.outcome-reporting-bias.org/</u>
- Data sharing guidance
- Recommendations for sharing qualitative data in trials

Global Health project awards

- Sylivia Nalubega, Soroti University, Uganda: The practice of pilot studies in informing the conduct of HIV clinical trials in sub Saharan Africa: a review of study protocols
- Naomi Waithira, MORU Tropical Health Network, University of Oxford, UK: *Exploring barriers to data reuse*

- Nandi Siegfried, MRC Alcohol, Tobacco and Other Drug Research Unit, South Africa: *Cultural competence in trial design and conduct*
- Mercy Chepkirui Terer, KEMRI-Wellcome Trust Research Programme, Kenya: Pilot implementation of Short Message Service for randomisation in a multisite pragmatic factorial clinical trial in Kenya (PRISMS Study)









Global Health project awards

- Sangeetha Paramasivan, University of Bristol, UK: Optimising Informed CONsent in clinical trials in low- and middle-income settings: feasibility of an adapted QuinteT Recruitment Intervention (QRI) in India (OrION-I)
- **Wigilya Mikomangwa**, Muhimbili University of Health and Allied Sciences, Tanzania: Assessment of the challenges encountered in implementing vaccine clinical trial methodologies in low income countries
- David Musoke and James O'Donovan, Makerere University, Uganda: Photovoice to explore community members perspectives regarding health and healthcare challenges in Mukono District, Uganda









MRC Doctoral Training Programme in Trials Methodology, 2021-2028



Statistics Computer science Data science Health informatics Health economics Psychology Social science **Behavioural science Bioethics**

International Clinical Trials Methodology Conference









THE TRIALS METHODS RESEARCH AGENDA: A PRIORITY SETTING EXERCISE, 2022

Inviting input from:

- members of the public
- patients
- researchers involved in clinical trials and/or trials methodology research
- clinicians and health professionals
- funders
- research ethics organisations
- those involved in the conduct of clinical trials (including investigators, research nurses, trials operations staff, statisticians, health economists, clinical trial pharmacists, regulators)
- editorial board members of journals that publish clinical trial protocols, clinical trials results and trials-relevant methodology



UK IRELAND SWITZERLAND FRANCE AUSTRALIA

Contact: sinead.holden@ucd.ie



UCD School of Medicine Scoil an Leighis UCD







Enabling lower carbon clinical trials: *Development and prototype testing of a method to quantify the carbon footprint of current clinical trials to inform future lower carbon clinical trial design*



TMRP – the future

- Partner organisations and Working Group Co-Leads
- Funding:
- TMRP Coordinator
- DTP 2021-2028
- Re-investment from ICTMC 2022



- Strengthening collaborations with: international organisations, Patient Research Partners, industry
- Future funding applications for TMRP and for specific projects
- ICTMC 2024 🙂
- Delivering impact of work to date

Impact of/KT for methods research

- What's been the most impactful methods research or guidance you are aware of, and why?
- What do we mean by 'impact'?
- Who or what do we want to be 'impacted'?
- Is there a translational gap?
- How can we achieve impact?
- How can we demonstrate impact?